A Spanish research project is testing whether myelin damage may begin before Alzheimer's becomes clinically obvious. The work looks beyond beta amyloid and tau, focusing on the insulating layer that helps nerve signals travel efficiently. Researchers are asking whether repairing myelin could protect memory and brain circuits.
The project involves CIC biomaGUNE and is led by Jordi Llop. Its radiochemistry and nuclear-imaging group is working with Carlos Matute's team at EHU/UPV. The researchers are testing compounds that may restore or protect myelin in rodent models, then assessing whether any repair improves cognitive behaviour. The work does not involve patient treatment; it investigates another possible mechanism of the disease.
Myelin surrounds the axons of neurons and acts as electrical insulation. When it deteriorates, signals travel more slowly and less effectively. Llop's group is examining whether these weakened connections help explain why brain networks lose efficiency even when the neurons are still present.
The biological link remains unresolved. Researchers have found degraded or deformed myelin in people with Alzheimer's, but they do not know whether that damage helps cause the disease or results from changes caused by it. The project investigates that question and looks for ways to prevent or repair these changes early.
The project is part of a broader shift in Alzheimer's research toward earlier, more precise biological assessment. Reporting on SEMNIM's nuclear-medicine discussions describes amyloid PET and tau PET as tools already used to help select patients and evaluate biological changes in clinical research and treatment. Myelin-targeted PET would examine a different process.
Detecting myelin damage is difficult. Standard brain imaging can examine the brain without surgery, but may miss subtle changes in the myelin sheath. The team is combining imaging with behavioural tests in animals to track whether protected myelin is linked to preserved memory or a smaller decline.
One basic tool is positron emission tomography, or PET, which uses small radioactive molecules as tracers. Here, the tracers are designed to detect changes in myelin instead of showing general brain activity. When myelin breaks down, it exposes structures that are normally hidden. The marker attaches to those structures and creates a detectable signal.
The approach could eventually allow researchers to monitor myelin repair without surgery in human subjects. That remains a future goal, with no established clinical use. For now, the work remains focused on models and on whether a measurable biological change is linked to better cognitive performance.
Early studies using these tools have detected Alzheimer's-associated changes in brain regions with high levels of myelin. The finding supports a wider view of the illness: Alzheimer's may involve problems with communication between neurons alongside protein accumulation. A brain network can contain the right cells and still work poorly if its signals no longer travel with enough speed and precision.
As reported by SINC, the researchers are seeking compounds that could restore myelin in rodents and testing whether the repair produces a cognitive benefit. Noticias de Gipuzkoa and Noticias de Álava have also covered the work; PARKe identifies it as a collaboration between CIC biomaGUNE's Jordi Llop group and Carlos Matute's team at EHU/UPV. If later studies confirm the findings in humans, the same imaging strategy could help detect changes earlier and track the disease more closely.
The project tests whether myelin damage is an early, treatable part of Alzheimer's or a secondary sign, without turning a promising hypothesis into a medical promise. Until animal results translate into human evidence, the conclusion must remain measured. Understanding the brain's connections may matter as much as tracking the proteins traditionally placed at the centre of the disease.
